Quince Therapeutics <QNCX.O>: Leerink Partners adjusts target price to $68 from $4 to reflect 1-for-20 reverse stock split
QNCX•Related News
Flotek says Puerto Rico power project work halts as PREPA reviews contract status
FTK•
Li Auto files HKEX next-day disclosure return reporting share repurchase at USD 6.21 each
LI•
Main Street Capital takes minority equity stake in Midstream Valve Partners in $39.3 million recapitalization
MAIN•
UBS Group discloses 3.02% stake in All for One Group
UBS•
Amer Sports Q2 revenue beats on segment growth
AS•